Zedoresertib and Lunresertib Combination Shows Promising Antitumor Activity
At the 2026 American Association for Cancer Research (AACR) Annual Meeting, early-phase clinical data revealed that the combination of Zedoresertib (ATR inhibitor) and lunresertib (WEE1 inhibitor) demonstrated significant antitumor activity ... Read More